XOMAP
XOMA Corporation
NASDAQ · Healthcare · Biotechnology · US
$24.98
+0.00%Year over year
Reported trailing growth
- Revenue
- -36.1%
- EBITDA
- +315.3%
- EBIT
- +113.8%
- EPS
- +469.0%
- Free cash flow
- +199.2%
- Operating cash flow
- +199.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +105.3%
- EBITDA
- +981.8%
- EBIT
- +128.5%
- Net income
- +329.4%
- EPS
- +192.7%
- Free cash flow
- +120.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026